| ncRNA name | PANDAR |
| ncRNA Category | lncRNA |
| ID | 101154753 |
| Ensembl | ENSG00000281450 |
| Synonyms | NA |
| Disease name | retinoblastoma (RB) |
| Species | Homo sapiens |
| Tissues/Cell_line | RB samples, normal retina samples; RPE cell line ARPE-19; RB cell lines WERI-RB1, Y79,SO-Rb50 and HXO-RB44 |
| Methods | transfection, qRT-PCR, CHIP assay, luciferase reporter assay, immunoblot , CCK-8 assay, flow cytometry, Caspase-3/-9 activity determination, xenograft, immunohistochemistry |
| Expression pattern | up-regulated |
| Functional description | PANDAR was increased in RB tissues and cells, and this upregulation was associated with advanced IIRC stage, positive optic nerve invasion, and lower differentiation grade in RB patients. PANDAR silencing yielded tumor suppressive effects both in vitro and in vivo. Importantly, PANDAR protects against mapoptosis partly by affecting Bcl-2/caspase-3 pathway. |
| PubMed ID | 29778422 |
| Year | 2018 |
| Title | SP1-induced upregulation of lncRNA PANDAR predicts adverse phenotypes in retinoblastoma and regulates cell growth and apoptosis in vitro and in vivo |
| Drug-related ncRNA | NO |
Copyright © Institution of Biomedical Big Data, Wenzhou Medical University All rights reserved.